FAQ

TD-4208

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
01220132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Pharmacological properties of revefenacin (TD‐4208), a novel, nebulized long‐acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and…
Revefenacin (TD-4208) is a novel, long-acting, and lung-selective muscarinic cholinergic receptor (mAChR) antagonist in… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2018
2018
Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized…
BACKGROUND Revefenacin (TD-4208) is a potent, lung-selective, long-acting muscarinic antagonist currently in development as a… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2017
Review
2017
Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
INTRODUCTION Long acting muscarinic receptor antagonists (LAMA) reverse airflow obstruction by antagonizing para-sympathetic… (More)
Is this relevant?
2013
2013
In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.
Tiotropium is currently the only once-daily, long-acting muscarinic antagonist (LAMA) approved in the United States and other… (More)
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
Is this relevant?
Review
2013
Review
2013
Long-acting muscarinic receptor antagonists for the treatment of respiratory disease.
The use of muscarinic receptor antagonists in the treatment of chronic obstructive pulmonary disease (COPD) is well established… (More)
Is this relevant?